-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The company has obtained another six production approvals.
Category:
发布时间：2019-04-23
【概要描述】
Recently, our company has obtained approval for six new peritoneal dialysis solution products, namely low-calcium peritoneal dialysis solution (lactate-based—G1.5%), low-calcium peritoneal dialysis solution (lactate-based—G2.5%), low-calcium peritoneal dialysis solution (lactate-based—G4.25%), peritoneal dialysis solution (lactate-based—G1.5%), peritoneal dialysis solution (lactate-based—G2.5%), and peritoneal dialysis solution (lactate-based—G4.25%).
Recently, our company has obtained approval for six new peritoneal dialysis solution products: low-calcium peritoneal dialysis solution (lactate-based, G1.5%), low-calcium peritoneal dialysis solution (lactate-based, G2.5%), low-calcium peritoneal dialysis solution (lactate-based, G4.25%), peritoneal dialysis solution (lactate-based, G1.5%), peritoneal dialysis solution (lactate-based, G2.5%), and peritoneal dialysis solution (lactate-based, G4.25%).
Peritoneal dialysis utilizes the peritoneum as a dialysis membrane: dialysate is infused into the peritoneal cavity, allowing for exchange of solutes between the blood in the peritoneal capillary spaces and the dialysate. Metabolic waste products and excess fluid retained in the body are removed from the body along with the spent dialysate, while essential substances are replenished via the dialysate. By repeatedly infusing fresh dialysate into the peritoneal cavity, the therapeutic goals of toxin removal, dehydration, correction of metabolic acidosis, and normalization of electrolyte imbalances can be achieved.
Over the years, peritoneal dialysis has evolved into an essential component of renal replacement therapy, alongside hemodialysis and kidney transplantation, owing to its simplicity, convenience, and proven efficacy. However, compared with developed countries, the utilization rate of peritoneal dialysis in China remains relatively low, indicating substantial room for market growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091